Higher Tattoo Exposure Linked to Reduced Melanoma Risk
MONDAY, Sept. 29, 2025 -- Higher tattoo exposure may be associated with reduced melanoma risk, according to a study published online Aug. 21 in the Journal of the National Cancer Institute.
Rachel D. McCarty, Ph.D., from the University of Utah in Salt Lake City, and colleagues conducted a population-based case-control study involving 1,167 melanoma cases and 5,835 frequency-matched controls to examine the relationship between tattooing and melanoma risk.
The researchers observed no strong association for ever receiving a tattoo with melanoma risk, but heavier tattooing exposure was associated with reduced risk. Compared with those who were never tattooed, overall melanoma risk was decreased among those who had received four or more tattoo sessions and individuals who had three or more large tattoos (odds ratios, 0.44 and 0.26, respectively). Individuals who had received their first tattoo before age 20 years had decreased invasive melanoma risk compared with never tattooed individuals (odds ratio, 0.48).
"The results that tattoos could decrease melanoma risk surprised us. But this isn't a black and white case of 'get more tattoos, and you could lower your risk of melanoma,'" McCarty said in a statement. "Instead, we need to do more research to understand what we are seeing and if this decreased risk is simply due to behavioral or physical factors, or if there could be beneficial immune responses associated with tattooing which lower melanoma risk."
One author disclosed receipt of personal fees from Epidemiologic Research & Methods, LLC.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Antithymocyte Globulin Cuts Loss of β-Cell Function in Type 1 Diabetes
MONDAY, Sept. 29, 2025 -- Antithymocyte globulin (ATG) 2.5 and 0.5 mg/kg reduces loss of β-cell function in young people with recent-onset type 1 diabetes, according to a...
Loss of Therapeutic Benefit Seen After Stopping Baricitinib in Type 1 Diabetes
MONDAY, Sept. 29, 2025 -- Two-year follow-up shows a loss of therapeutic benefit when baricitinib treatment is stopped in type 1 diabetes (T1D), according to a study presented at...
AAP: TikTok 'Benadryl Challenge' Fueling Rise in Diphenhydramine-Related Adverse Events
MONDAY, Sept. 29, 2025 -- Monthly reports of diphenhydramine-related adverse events were more common after April 2020, coinciding with introduction of the TikTok 'Benadryl...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.